{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:41:31Z","timestamp":1792978891119,"version":"4.5.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40265-024-02125-1","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T02:28:59Z","timestamp":1734661739000},"page":"97-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Xeligekimab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"5","key":"2125_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40257-024-00874-z","volume":"25","author":"ND Boswell","year":"2024","unstructured":"Boswell ND, Singla S, Gordon KB. Sequencing of targeted therapy in psoriasis: does it matter? Am J Clin Dermatol. 2024;25(5):795\u2013810.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2125_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.bbrc.2019.07.078","volume":"517","author":"Y Shan","year":"2019","unstructured":"Shan Y, Shi K, Qian X, et al. Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A. Biochem Biophys Res Commun. 2019;517(2):303\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"2125_CR3","unstructured":"Genrix (Shanghai) Biopharmaceuticals. Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. voluntarily discloses the announcement on the approval of celicimab monoclonal antibody for the indication of moderate to severe plaque psoriasis [media release]. 27 Aug 2024. https:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2024-08-27\/688443_20240827_J535.pdf."},{"key":"2125_CR4","unstructured":"Genrix Bio. Xeligekimab injection (Jinlixi\u00ae): Chinese prescribing information. 2024. http:\/\/www.genrixbio.com\/upload\/80\/d8e8e3bcf99cca548f3ca1674377ab.pdf. Accessed 12 Nov 2024."},{"key":"2125_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6129","author":"Q Meng","year":"2024","unstructured":"Meng Q, Wang W, Zhang L, et al. Population pharmacokinetics of xeligekimab: an anti-IL-17A monoclonal antibody, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2024. https:\/\/doi.org\/10.1002\/jcph.6129.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2125_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/bjd\/ljae062","volume":"191","author":"L Cai","year":"2024","unstructured":"Cai L, Jiang C, Zhang G, et al. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2024;191(3):336\u201343.","journal-title":"Br J Dermatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02125-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:00:34Z","timestamp":1737079234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02125-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2125"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02125-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"13 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}